Assessment of initial vancomycin dosing in neonates

Area of Science:

• Neonatal pharmacology
• Pediatric infectious diseases
• Clinical pharmacy

Background:

• Vancomycin is the recommended treatment for late-onset sepsis caused by coagulase-negative Staphylococcus in neonates.
• Current empirical vancomycin dosing may not consistently achieve therapeutic trough levels.

Purpose of the Study:

• To evaluate the effectiveness of an existing empirical vancomycin dosing regimen in neonates.
• To revise the vancomycin dosing regimen to improve target trough level achievement.

Main Methods:

• Pharmacokinetic analysis of vancomycin doses and trough levels in neonates.
• Calculation of initial and extrapolated trough levels.
• Assessment of doses required to achieve target levels (10-20 mg/L).

Main Results:

• Only 34.2% of neonates achieved target vancomycin trough levels with the initial regimen (mean 8.7 mg/L).
• Analysis indicated a need to increase empirical vancomycin doses across all neonatal age groups.
• A revised regimen (20-40 mg/kg/day) is predicted to achieve target levels in 72% of neonates (mean 15.4 mg/L).

Conclusions:

• The previous vancomycin dosing regimen was inadequate for achieving target trough levels in neonates.
• The modified empirical vancomycin regimen is predicted to enhance target level attainment and increase mean trough levels.
• Clinical validation of the revised regimen in an independent cohort is necessary.